When advising women about adjuvant therapy, clinicians should consider the adverse effect profiles of tamoxifen (venous thromboembolism and endometrial cancer, polyps,
and hyperplasia)
and AIs (osteoporosis, fractures,
and arthralgias). Switching from tamoxifen to an AI (or vice versa) might be appropriate if adverse effects become intolerable or precipitate nonadherence.
Clinically important differences have not been shown among currently marketed AIs.